have diabetes mellitus [3] , and persons who are receiving immunosuppressant medications or who have illness-related immunosuppression (e.g., HIV infection or a hematologic malignancy) [1, 2] .
In Arizona, the number of cases of coccidioidomycosis has increased annually for several years [4] [5] [6] [7] , and the incidence of symptomatic coccidioidomycosis is higher among persons aged у60 years [8] or у65 years [7] than among those aged !60 years or !65 years, respectively. In addition, advanced age has been identified as a risk factor for severe pulmonary coccidioidomycosis [9] and mortality [10] . However, the effects of comorbid conditions in the elderly population with coccidioidomycosis and on the course of infection have not been examined.
The increased risk for and increased severity of various infections in the elderly population have been well documented [11] . Both may be due, in part, to agerelated immune dysfunction, which is primarily characterized by a decrease in cell-mediated immunity. Cellmediated immunity is the primary defense against coccidioidomycosis [1] ; thus, it is reasonable to con-clude that coccidioidomycosis may have different characteristics in elderly populations than in younger populations. We sought to clarify whether the apparent differences in clinical coccidioidomycosis illness in elderly patients, compared with coccidioidal illness in a younger population, were associated with the effects of advanced age or with the presence of various comorbid conditions.
METHODS
We identified all patients with positive coccidioidal serologic test, culture, or pathologic test results, as reported by our institution (Mayo Clinic; Scottsdale, AZ) to the Arizona Department of Health Services (Phoenix, AZ) from January 1999 through October 2003. The charts of these patients were reviewed retrospectively, and details were abstracted regarding previous medical history, coccidioidal illness (i.e., symptoms and requirement for hospitalization), results of diagnostic tests (i.e., serologic, radiographic, microbiologic, and histopathologic tests), treatment (i.e., medical, surgical, or none), and condition during follow-up (i.e., improved, progressed, relapsed, or deceased).
Patients were defined as immunosuppressed if they had any of the following medical conditions or treatments: HIV infection, receipt of a solid-organ or hematologic transplant, hematologic malignancy, cancer treated by chemotherapy (if chemotherapy was administered within 30 days before the onset of coccidioidal illness), or receipt of immunosuppressive medication. Persons with diabetes mellitus were so designated if the medical record documented that the diagnosis was made before the onset of coccidioidal illness or within 30 days after the initial presentation.
Patients were also defined as having established care at our primary practice after they had undergone у2 visits with a primary care physician (i.e., a physician practicing in any of the following divisions of our practice: family medicine, general internal medicine, and select internal medicine subspecialities that provide primary care to some patients) before the onset of symptoms of coccidioidal disease.
Serologic testing. We used a few different serologic methods for the diagnosis of coccidioidomycosis [12, 13] . The EIA to detect IgM and IgG antibodies was a test kit from Meridian Bioscience (Pemire Coccidioides EIA). The Laboratory Branch complement fixation test from the Centers for Disease Control and Prevention was used to detect IgG antibodies, as described elsewhere [12, 13] . An immunodiffusion test kit (immunodiffusion reagents for serodiagnosis of coccidioidomycosis) manufactured by Gibson Laboratories was used to detect IgG antibodies using antigen F. As of June 2002, our laboratory used an immunodiffusion test kit (Coccidioides immunodiffusion systems) manufactured by Meridian Bioscience to detect both TP (early IgM) antibodies and F (late IgG) antibodies.
Statistical analysis. The rates of occurrence for several variables were compared between the 2 patient groups (age, !60 years vs. у60 years). We compared demographic characteristics, manifestations of illness, results of diagnostic tests (i.e., serologic, radiologic, and histopathologic tests and cultures), treatment, and outcomes of the coccidioidal illness between the 2 age groups using the x 2 test for categorical variables and Fisher's exact test for small samples. Unadjusted and adjusted ORs (with 95% CIs) were calculated by logistic regression. A P value of !.05 was considered to be statistically significant. Statistical analysis was conducted using SAS software, version 9.0 (SAS Institute).
RESULTS
A total of 396 patients were identified for chart review; 186 patients were aged !60 years, and 210 patients were aged у60 years. With regard to demographic characteristics, the 2 groups were significantly different, in that the older age group included more persons of white race (97% vs. 83%;
) and in-P ! .001 cluded more patients with comorbid conditions, including cancer, cardiovascular and lung disease, tobacco use, and immunosuppression (table 1) . No differences were observed between the older and younger age groups when the following characteristics of coccidioidal illness were considered: pulmonary infection resulting in the presence of у1 cavitary lesion identified radiographically, disseminated coccidioidomycosis, requirement for hospitalization for disease management, or other findings from a diagnostic evaluation (e.g., positive serologic, microbiologic, or histopathologic test results). In addition, patients in both age groups were equally likely to have received medical versus surgical treatment for coccidioidal infection, to have experienced relapse, to have had progressive disease, and to have had infection associated with death (table 2) .
After adjustment for immunosuppression, diabetes mellitus, nonwhite race, tobacco use, asymptomatic seropositivity, and disseminated illness, we found no statistically significant differences between the older and younger age groups with respect to any of the same aspects of coccidioidal illness, including disseminated infection, hospitalization, need for medical or surgical treatment, relapsed or progressive illness, or death due to coccidioidomycosis (data not shown).
We also looked at immunosuppressed patients, without respect to age, and compared their courses of infection with those of nonimmunosuppressed (i.e., healthier) patients of all ages ( ) than did nonimmunosup-P ! .001 pressed patients.
A univariate logistic regression analysis was performed to examine the potential effects of multiple comorbid conditions on 3 important characteristics of coccidioidal illness (namely, disseminated infection, requirement for hospitalization to manage illness, and death due to coccidioidal infection) (table 4) . For all age groups, men were more likely than women to require hospitalization ( ), white patients were more likely to P p .03 experience disseminated infection than were nonwhite patients ( ), and persons with diabetes were more likely than P p .04 persons without diabetes to experience disseminated infection ( ) and death due to coccidioidomycosis ( ). P p .049 P p .03 Immunosuppressed persons were more likely than nonimmunosuppressed persons to experience disseminated infection ( ), hospitalization ( ), and death due to cocci-P p .05 P ! .001 dioidal infection ( ). A multivariate logistic regression P ! .001 analysis was then performed to examine the effects of age, immunosuppression, and any potential interaction of age and immunosuppression (table 5). Immunosuppression was the only factor found to have a statistically significant impact on the outcomes of coccidioidal infection.
To gain an understanding of the potential bias of the referral practice, we conducted a secondary chart review to classify patients as having established primary care at our institution ( ) or as being tertiary care referral patients ( ). n p 183 n p 213 Among patients aged у60 years, there were no statistically significant differences in demographic characteristics of the population or in the manifestations, treatment, or outcomes of coccidioidal infection between primary care patients and referral practice patients. In contrast, in the younger group, referral patients were more likely than primary practice patients to have disseminated coccidioidomycosis (16% vs. 4%; P p ), to require treatment (73% vs. 56%; ), and to re-.01 P p .04 quire hospitalization (28% vs. 13%;
). This latter re-P p .02 ferral group, however, did not experience a higher frequency of relapse, disease progression, or death due to coccidioidomycosis. Logistic regression modeling showed that the presence of this small subgroup of patients within the control group did not change the outcome of the investigation (i.e., it was not the reason for the lack of age group-related differences in coccidioidomycosis outcomes).
DISCUSSION
Coccidioidomycosis is a fungal infection acquired by inhalation of airborne fungal arthrospores of Coccidioides species in the desert areas of the southwestern United States and northern Mexico-regions that constitute the major areas of endemicity. In general, ∼60% of persons with evidence of recent exposure and skin test conversion are asymptomatic, whereas the remaining 40% have mild-to-severe pulmonary illness. Depending on the population being studied, 1%-6% of patients manifest extrapulmonary dissemination [1] . In recent years, the incidence of coccidioidomycosis has increased in the general populations of Arizona [7] and California [14] ; at the same time, the number of persons aged у65 years in the United States-and, specifically, in Arizona-has increased [15] . Importantly, the incidence of reported coccidioidal illness in Arizona is higher in each incremental age group, with the highest incidences found in the oldest age groups [7, 8] .
During the period 1995-1996, in Kern County, California [9] , age was found to be an independent risk factor for severe pulmonary coccidioidomycosis (defined as radiographically documented pneumonia resulting in hospitalization) in a multivariate analysis of factors that included diabetes, smoking, male sex, African American race, and low socioeconomic status. A study of acute symptomatic coccidioidomycosis in persons aged у60 years [8] identified recent relocation to Arizona or an underlying medical condition as risk factors for development of the disease.
The definition of the term "elderly" has proven to be problematic, because there is no specific age cutoff that defines the term definitively. We elected to classify age groups by decade, and the age breakpoints used in this study were chosen to align with those reported in the only published report of a study dedicated to the analysis of advanced age and coccidioidomycosis in Arizona [8] . In analyzing our data, we assessed many age breakpoints but identified no differences in findings when different breakpoints were used (data not shown).
Elderly populations have an increased risk for and severity of various infections [11] . This vulnerability may be associated with an immune dysfunction characterized primarily by a decline in cell-mediated immunity. Several factors may contribute to this immunosenescence. During the aging process, the production of T cell progenitors decreases, and thymic involution leads to decreased levels of newly generated mature T cells. Cytokine synthesis or activity may also decrease with age [16] . In addition to changes in T cell immunity, the generation of B cells and humoral function is thought to be decreased as a downstream result of the decline in T cell function. Antigenpresenting cell function appears to be preserved in elderly persons [17] .
Protection against coccidioidomycosis in humans is mediated by the very same cell-mediated immunity-namely, T cellassociated immune responses-that is impaired in elderly persons. Specifically, the defense against coccidioidomycosis depends on the cumulative response of processing and presenting antigens by macrophages or dendritic cells, leading to the induction of T cells to produce IFN-g and other helper T cellassociated cytokines. These cytokines, in turn, provide the signals for recruiting and activating immune effector cells [1] .
The above notwithstanding, the presence of comorbid conditions in elderly populations has been identified as a better predictor of impaired immunity than is chronological age [18] . Therefore, critical to any discussion of the risk and severity of infection in the elderly population is consideration of the effect of comorbid illnesses on the clinical manifestations of infection-particularly diabetes, malignancy and its treatment, use of immunosuppressive medications, and tobacco use. Because of the influence of comorbidity and immunosenescence, elderly persons often have altered clinical manifestations of infection that result in delayed diagnosis [19] . The lack of information about comorbid conditions impedes the interpretation of select studies of coccidioidomycosis in elderly patients [10] .
After adjustment for comorbid conditions (particularly immunosuppression), our data showed no statistically significant differences between the older and younger populations with respect to the characteristics of coccidioidal infection. Logistic regression analysis did not find that the outcomes were influenced by age or that there was any interaction between age and immunosuppression. However, confounding influences may have obscured differences. Perhaps our patient population, with its easy access to medical care, sought care for minor symptoms and received earlier diagnosis and treatment than might be expected for other populations. Alternatively, perhaps our patients are less frail than their age-matched cohorts in the general population. However, the lack of data needed to measure these characteristics makes such conclusions purely speculative.
Another potentially confounding influence was the presence of a referral bias. Although we saw no differences in coccidioidomycosis between primary care and referral populations in patients in the older age group, the referred patients in the control group (i.e., patients aged !60 years) were significantly more likely to have disseminated or progressive coccidioidomycosis and to require hospitalization. These latter findings may have been the very reason for referral to our institution. Therefore, we performed subsequent calculations to assess the effect of this biased referral subgroup on the outcomes of the study but found no statistically significant impact on the study outcomes.
In summary, a retrospective review of select clinical manifestations of coccidioidomycosis in patients aged у60 years, compared with those in patients aged !60 years, did not identify any significant differences between the age groups when they were considered as a whole or when they were adjusted for various comorbid conditions. However, clinically important and significant differences in coccidioidal manifestations were found between immunosuppressed patients aged !60 years and both nonimmunosuppressed patients aged у60 years and, to a lesser extent, nonimmunosuppressed patients aged !60 years. Because of the increase in the elderly population and the continuing increase in the incidence of coccidioidomycosis among elderly persons, future studies are needed to further delineate answers to crucial questions that will lead to the optimal approach to, management of, and prevention of coccidioidomycosis in all populations.
